Russia Moves Toward Launch of First Recombinant Allergy Vaccine

Published on March 27, 2026

Russia is on the verge of a significant breakthrough in allergy treatment with plans to grant temporary registration for its first recombinant allergy vaccine as early as the second quarter of 2026. This pivotal announcement was made , the head of the Federal Medical-Biological Agency, during a recent scientific press conference highlighting major advancements in life sciences and the implementation of Russia’s national research strategy.

Skvortsova provided updates on the progress of the vaccine’s clinical development, stating, “We expect temporary registration in the second quarter of this year. At the same time, patient recruitment for the third phase of clinical trials is nearing completion. After the 2026 pollen season, we hope to apply for permanent registration of this vaccine.”

The anticipated approval marks a key milestone in Russia’s ongoing efforts to innovate in the field of immunological treatments. Addressing the growing issue of allergies, particularly pollen-related ones, this new vaccine aims to provide a more effective solution for millions of individuals suffering from allergic reactions.

As the third phase of clinical trials comes to a close, the focus will shift toward monitoring the vaccine’s efficacy and safety in real-world conditions. With a timeline set for the vaccine’s temporary registration, experts are optimistic about its potential impact on public health.

In a country where allergy rates are rising, the introduction of this recombinant vaccine could represent a turning point for many individuals affected conditions. The scientific community is closely watching these developments, with the upcoming pollen season serving as a pivotal moment for both researchers and patients alike.

Related News